Literature DB >> 9557701

Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle.

R E Kiernan1, A Ono, G Englund, E O Freed.   

Abstract

The matrix protein of human immunodeficiency virus type 1 (HIV-1) has been reported to play a crucial role in the targeting of the Gag polyprotein precursor to the plasma membrane and in the incorporation of viral envelope glycoproteins into budding virions. In this report, we present evidence that mutation of a highly conserved Leu at matrix amino acid 20 blocks or markedly delays virus replication in a range of cell types, including T-cell lines, primary human peripheral blood mononuclear cells, and monocyte-derived macrophages. These mutations do not impair virus assembly and release, RNA encapsidation, or envelope glycoprotein incorporation into virions but rather cause significant defects in an early step in the virus life cycle, as measured by single-cycle infectivity assays and the analysis of viral DNA synthesis early postinfection. This infectivity defect is independent of the type of envelope glycoprotein carried on mutant virions; similar results are obtained in pseudotyping experiments using wild-type or truncated HIV-1 envelope glycoproteins, the amphotropic murine leukemia virus envelope, or the vesicular stomatitis G protein. Intriguingly, matrix residue 20 mutations also increase the apparent binding of Gag to membrane, accelerate the kinetics of Gag processing, and induce defects in endogenous reverse transcriptase activity without affecting virion density or morphology. These results help elucidate the function of matrix in HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557701      PMCID: PMC109641          DOI: 10.1128/JVI.72.5.4116-4126.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  Differential membrane binding of the human immunodeficiency virus type 1 matrix protein.

Authors:  W Zhou; M D Resh
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

2.  Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures.

Authors:  D P Bolognesi; R Luftig; J H Shaper
Journal:  Virology       Date:  1973-12       Impact factor: 3.616

3.  Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells.

Authors:  H Zhang; G Dornadula; R J Pomerantz
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures.

Authors:  M S McBride; A T Panganiban
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Pathway of vesicular stomatitis virus entry leading to infection.

Authors:  K S Matlin; H Reggio; A Helenius; K Simons
Journal:  J Mol Biol       Date:  1982-04-15       Impact factor: 5.469

6.  The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes.

Authors:  J H Simon; M H Malim
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Direct interaction between the envelope and matrix proteins of HIV-1.

Authors:  P Cosson
Journal:  EMBO J       Date:  1996-11-01       Impact factor: 11.598

8.  Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.

Authors:  D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Cytoskeleton-associated Pr65gag and retrovirus assembly.

Authors:  C A Edbauer; R B Naso
Journal:  Virology       Date:  1983-10-30       Impact factor: 3.616

10.  Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly.

Authors:  C P Hill; D Worthylake; D P Bancroft; A M Christensen; W I Sundquist
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

View more
  83 in total

1.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.

Authors:  A Ono; E O Freed
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Plasma membrane rafts play a critical role in HIV-1 assembly and release.

Authors:  A Ono; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

5.  Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Authors:  S Tang; T Murakami; B E Agresta; S Campbell; E O Freed; J G Levin
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation.

Authors:  A Deora; L Ratner
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Somatic cell mutants resistant to retrovirus replication: intracellular blocks during the early stages of infection.

Authors:  G Gao; S P Goff
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

8.  A human nuclear shuttling protein that interacts with human immunodeficiency virus type 1 matrix is packaged into virions.

Authors:  K Gupta; D Ott; T J Hope; R F Siliciano; J D Boeke
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Interaction of Moloney murine leukemia virus matrix protein with IQGAP.

Authors:  Juliana Leung; Andrew Yueh; Frank S K Appah; Bing Yuan; Kenia de los Santos; Stephen P Goff
Journal:  EMBO J       Date:  2006-04-20       Impact factor: 11.598

10.  Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Peter Y Mercredi; Sampson K Kyere; Justin Donlan; Tsutomu Murakami; Michael F Summers; Simon Cocklin; Eric O Freed
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.